The real comparison is with Eli Lilly and Companys orforglipron: both are oral, small molecules, and direct GLP-1R agonists, and Lilly is close to the finish line with an FDA decision expected in April 2026
Molecular insights into SARS-CoV2-induced alterations of the gut/brain axis
"Short-term side effects were not observed in this small population, and they did not evaluate if it actually worked for a specific condition or if it was safe for long-term use." Jamie Richardson, BVetMed, head of veterinary medicine at Small Door Veterinary, shares the same concerns
Key Takeaways A recent NAD decision underscores that advertising compounded drugs in a way that implies they share the benefits of FDA-approved medications will likely be deemed deceptive by regulators
We specialize in helping women achieve real results through medically guided GLP-1 weight loss treatment
Progesterone may also be recommended for women who still have a uterus when medically appropriate